Citations

Clear

3032 citation(s) found for "Ma, Kevin".

Metformin modulates the phenotypes of tumor-associated macrophages in glioblastoma in a context-dependent manner by promoting the homeostasis of macrophages
Das, Ashish , Mahfooz, Sadaf , Wang, Fei, Guan, Bingjie , Xu, Benhua, Zhang, Chi (Kevin), Wang, Zi, Jia, Yuanyuan, Lin, Chi, Wang, Fei , Chalbatani, Ghanbar Mahmoodi

Mayo Clinic

Frontiers in Oncology | August 14, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1834973 | PMID 42666173 Get It

Background Glioblastoma (GBM) remains the most aggressive primary adult brain cancer attributed to its immunosuppressive nature. Radiation therapy (RT) and concurrent temozolomide chemotherapy are the standard treatments for GBM. Emerging evidence indicates that metformin has potential as an anti-tumor agent that can reshape the immune landscape across various malignancies. We thus postulate that metformin may enhance the anti-tumor effect of RT by modulating the immunosuppressive milieu in GBM. Methods We first explore multiple in vitro conditions, with or without pre-induction, and mimicked a tumor microenvironment to demonstrate a highly context-dependent effect of metformin on the polarization of bone marrow-derived macrophages (BMDMs). We then investigated the antitumor activity and immune-modulatory effects of metformin in combination with RT in GBM-bearing mice. Results The in vitro experiment showed that metformin inhibited the immunosuppressive effects of IL-4/IL-13 but also the immunostimulatory effects of Lipopolysaccharide (LPS) on BMDMs, demonstrating bidirectional immunomodulatory properties that depend on the baseline inflammatory stimulus. In tumor cell co-culture environment, metformin exhibited context-dependent immunoregulatory effects, predominantly promoting M1-associated activation. Notably, concurrent metformin treatment counteracted M2 polarization typically induced by the tumor microenvironment. In a high m-MCSF inducted M2-dominated condition, metformin preferentially shifted the highly polarized M2 phenotype toward an M1-like state in a time and dose-dependent manner but with limited promotion of M1 subtype maturation. RNAseq results on BMDM treated with metformin showed increased homeostasis. Metformin showed dose-dependent immunomodulatory effects when combined with RT in vitro . In syngeneic GBM mouse models, concurrent metformin + RT significantly prolonged survival and reduced tumor burden by reprogramming tumor-associated macrophages (TAMs), elevating intratumoral CD8+ T-cell infiltration and the CD8+/Treg ratio, increasing circulating CD8+ T cells, reversing RT-induced expansion of monocytic myeloid-derived suppressor cells (mMDSCs), and expanding CD4+ and CD8+ effector memory populations in peripheral blood. Conclusion Metformin demonstrates inhibitory effects on M2 phenotype of macrophages. However, it is not a simple M2 inhibitor; instead, it functions primarily as a neutralizer of highly polarized macrophage states by promoting transcriptomic homeostasis. This context-dependent activity enables metformin to relieve the profoundly immunosuppressive TME of GBM to potentiate the anti-tumor effects of RT and by enhancing systemic immune memory.
Risk Factors for Coronavirus Disease 2019 Hospitalization and Vaccination Impact Among Pediatric Solid Organ Transplant Recipients in the United States
Thomas, Sanya J. , Bocchini, Claire, Brammer, Caitlin, Brock, Guy, Calimaran, Abigail, Dallas, Ronald, Downes, Kevin J., Ferrolino, Jose A., Haque, Md Rejuan , Kaur, Ishminder , Kumar, Madan , Landry, Meghan, Lerret, Stacee, Maron, Gabriela M., Minniear, Timothy D., Muller, William J., Munoz, Flor M., Otto, William R., Perkins, Kerrigan, Ristagno, Elizabeth H., Sharova, Anna, Siegel, Katherine, Song, Eunkyung , Valladares, Marion, Wilson, Natasha A., Yoshida, Allison, Almeida, Natalia E. Castillo , Bocchini, Claire Elizabeth , Brammer, Caitlin N , Brock, Guy , Dallas, Ronald H. , Downes, Kevin J. , Ferrolino, Jose Amadeo A , Huppler, Anna R. , Landry, Meghan, Lerret, Stacee Marie , Marón, Gabriela , Minniear, Timothy Dean , Muller, William J. , Muñoz, Flor M., Otto, William R , Ristagno, Elizabeth H. , Wilson, Natasha, Shimamura, Masako

Mayo Clinic

Transplant Infectious Disease | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/tid.70303 | PMID 42596081 Get It

ABSTRACT Background While vaccination is a key strategy to mitigate the severity of coronavirus disease 2019 (COVID‐19) in children, the risk factors for symptomatic, medically attended (hereon referred to as “symptomatic”) COVID‐19 and the impact of vaccination are not well defined among pediatric solid organ transplant recipients (PSOTR). Methods PSOTR aged six months through 21 years at 11 centers in the Pediatric Infectious Diseases Transplant Network (PIDTRAN) were analyzed retrospectively for symptomatic COVID‐19 between July 2021 and May 2023. Using a Cox proportional hazards model, risk factors associated with COVID‐19‐associated hospitalization, in‐hospital oxygen use, mechanical ventilation, and the impact of COVID‐19 vaccination were analyzed. Results Of 1370 PSOTR, 410 (29%) had symptomatic COVID‐19 infection. Among those with symptomatic infection, 115 (28%) were hospitalized, 35 required in‐hospital oxygen, and three required mechanical ventilation. In the study, 45% were unvaccinated against COVID‐19. Compared to unvaccinated PSOTR, incompletely vaccinated PSOTR had 56% lower hazard (95% CI 0.26, 0.72, p = 0.001) of COVID‐19‐associated hospitalization whereas completely vaccinated did not have a statistically significant difference in hazard of hospitalization. Receipt of at least one dose of the bivalent vaccine was also associated with 92.5% lower hazard (95% CI 0.010, 0.55, p = 0.011) of hospitalization. Risk factors for hospitalization included chronic kidney disease, underlying heart disease, neurodevelopmental delay, and lymphocytopenia. Conclusions Most PSOTR with symptomatic COVID‐19 did not require hospitalization or respiratory support. Several comorbidities and lymphocytopenia are associated with severe COVID‐19 in PSOTR. COVID‐19 vaccination, mostly, protected PSOTR against COVID‐19‐associated hospitalization, but vaccine uptake among PSOTR was low. image
Implantation of Deep Brain Stimulator Through Polyetheretherketone (PEEK) Cranioplasty
Odorico, Scott K. , Tabatabaei, Kevin, Cherukuri, Sai , Miller, Kai, Gibreel, Waleed, Gharavi, Aidin , Gharavi, Aidin, Tabatabaei, Kevin , Gibreel, Waleed

Mayo Clinic

Journal of Craniofacial Surgery | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/scs.0000000000013255 | PMID 42584182 Get It

Background: Polyetheretherketone (PEEK) is a commonly used material for cranioplasties due to its advantages over other materials and autologous bone grafts. PEEK has an increased malleability, which increases postoperative aesthetics and adapts well to the cranial contours; it is also associated with a lower rate of infection when compared with autologous cranioplasties. Despite these benefits, there is limited information on the practical aspects of modifying PEEK cranioplasties after their initial placement. Case Series: We present 2 cases of patients who had previously undergone PEEK cranioplasty being treated with deep-brain stimulation (DBS), which was placed through their PEEK implant. The first was an 18-year-old male who had previously undergone cranial vault closure with bone grafts following a craniotomy. Later, when a deep-brain stimulator was planned, it was discovered that the bone grafts had significant resorption and a lack of structural integrity. Therefore, bone grafts were replaced with a custom PEEK implant cranioplasty before the DBS electrodes were placed via drilling through the PEEK implant to access the brain at a later surgery. The second patient was a 39-year-old male who developed epilepsy after a stroke, requiring craniotomy. DBS was unable to be performed initially due to significant resorption of the patient’s native bone. Therefore, a PEEK cranioplasty was performed in preparation for a staged, subsequent placement of DBS electrodes through the implant. Both patients recovered uneventfully following surgery, with noticeable improvement in functional (reduction in seizure frequency) and aesthetic outcomes. Systematic Review: A literature review was conducted using PubMed with keywords related to PEEK cranioplasties. After screening titles, abstracts, and full-text papers, it was found that 3 previously documented cases have involved drilling through PEEK implants: one by Mallela et al, involving SEEG electrode placement; one by Marrone et al, concerning a burr hole for evacuating a chronic subdural hematoma; and one by Ledesma et al, regarding the placement of subdural grid electrodes. Conclusions: This case series highlights how PEEK cranioplasties can be drilled through for therapeutic procedures, such as DBS electrode implantation, without compromising their structure. These cases illustrate the versatility, safety, and adaptability of PEEK implants for additional necessary interventions.
Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography
Li, Jiahui , Wu, Hao , Glaser, Kevin J. , Ou, Fang‐Shu , Manduca, Armando , Venkatesh, Sudhakar K. , Sirlin, Claude B. , Shah, Vijay H. , Ehman, Richard L. , Wu, Hao , Sirlin, Claude B. , Loomba, Rohit , Ehman, Richard , Allen, Alina M , Manduca, A , Ou, Fang-Shu , Venkatesh, Sudhakar K , Li, Jiahui , Loomba, Rohit , Allen, Alina M. , Yin, Meng , Wu, Hao

Mayo Clinic

Hepatology Communications | August 11, 2026 | Volume: 10 | Issue: 9 | Pages: No page available

10.1097/hc9.0000000000001024 | PMID 42579768 Get It

Background: Accurate identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) at risk of disease progression (at-risk MASH) is critical for guiding resmetirom and semaglutide therapy. Inconsistent definitions of at-risk MASH complicate clinical risk classification and comparisons across studies. This study aimed to standardize the definition of at-risk MASH and propose optimized MRE-based liver stiffness (LS-MRE) cutoffs to improve noninvasive risk stratification and better guide pharmacotherapy. Methods: In this prospective study, 413 patients with suspected or diagnosed MASLD from two medical centers underwent liver biopsy and MRE. Results: A simplified definition of at-risk MASH (MASH with fibrosis stage≥2) identified a broader group of patients requiring clinical attention than a stricter definition requiring NAFLD Activity Score≥4 with ≥1 point in steatosis, inflammation, and ballooning (n=122 vs. 77). LS-MRE alone showed the highest diagnostic accuracy for identifying at-risk MASH using the simplified definition (AUC 0.91 [0.87, 0.95]) and cirrhosis (AUC 0.93 [0.88, 0.99]), compared with FIB-4 and individual laboratory parameters (AST, ALT, and platelet count) ( p <0.01 for all, paired DeLong tests). Optimized LS-MRE cutoffs (2.8–6.4 kPa) captured 25 additional biopsy-proven pharmacotherapy candidates (28% of all eligible patients) compared to AASLD guidelines–recommended cutoffs (3.1–4.4 kPa), improving sensitivity (80% vs. 50%) with acceptable specificity (73% vs. 88%). Conclusions: A simplified definition of at-risk MASH enables broader identification of treatment candidates. LS-MRE demonstrates excellent diagnostic performance and improves noninvasive risk stratification when paired with optimized cutoffs. These findings support the use of MRE to guide resmetirom and semaglutide eligibility and improve access to emerging therapies.
Use of Wireless Smart Devices in Remote Monitoring of Chronic Wounds: A Scoping Review
Tabatabaei, Kevin , Gharavi, Aidin , Wanberg, Erik J. , Mayer, Dieter , Najafi, Bijan, Alavi, Afsáneh , Mayer, Dieter O , Alavi, A , Wang, S C , Najafi, Bijan , Gharavi, Aidin

Mayo Clinic

Wound Repair and Regeneration | August 6, 2026 | Volume: 34 | Issue: 4 | Pages: No page available

10.1111/wrr.70194 | PMID 42559742 Get It

ABSTRACT The integration of Internet of Things devices in medicine has paved the way for novel diagnostic and therapeutic solutions that offer ‘smart’ capabilities, especially for at‐home wound monitoring. Such capabilities include increasing portability, diminished gaps in care through continuous analysis, and real‐time programmable manipulation of device parameters to intervene more rapidly. This scoping review explores the landscape of Internet of Things devices, including smart bandages, wearable and skin‐interfaced sensors, and mobile app‐connected devices, specifically designed for chronic wound monitoring in a remote, at‐home setting. We reviewed literature from PubMed, IEEE Xplore, Scopus, and Web of Science, using keywords related to Internet of Things and chronic wound care. The evaluation criteria focused on biomarkers analysed, Internet of Things connectivity technology, experimental models used for device validation, and unique device strengths or weaknesses. Our review identified 52 unique studies comprising 77 data entries across five biomarker categories: gas and oxygen saturation, pH, metabolic markers, biophysical parameters of the wound microenvironment, and molecular markers of inflammation or infection. These devices span a wide landscape of biomarkers analysed to predict and monitor wound recovery, with the potential to improve patient outcomes through personalised treatment and timely interventions. However, many devices were never validated clinically on humans and faced limitations in power delivery, accuracy, stability, and reliability that challenge their potential usability in humans for wound monitoring. This review provides a comprehensive understanding of the potential and limitations of Internet of Things devices in at‐home wound care, highlighting areas for future research and development.
Prednisone in the Management of Pericarditis A Systematic Review
Razeghi, Ghazal , Genadri, Alfred E, Abumustafa, Yousef, Mohottalage, Dhanuddara , Tahvildar, Nina, Shirobokov, Valerie , Carballo, Corina, Hakimjavadi, Ramtin , Cremer, Paul , Mardigyan, Vartan , Kafil, Tahir S , Pantieras, Falia, Kafil, Tahir, Cremer, Paul C , Ahmed, Faisal Awad , Visintini, Sarah , Boczar, Kevin E.

Mayo Clinic

Journal of Cardiovascular Pharmacology | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/fjc.0000000000001867 | PMID 42552090 Get It

Background: Corticosteroids are widely used in pericarditis despite guideline recommendations reserving them for select indications. Observational studies have reported inconsistent associations between corticosteroid use and pericarditis recurrence, and optimal dosing and tapering strategies remain unclear. We conducted a systematic review of oral corticosteroids for acute or recurrent pericarditis to characterize patterns of treatment and evaluate the association between corticosteroids and pericarditis recurrence across different disease contexts. Methods: MEDLINE, EMBASE, CENTRAL, and Scopus were searched from inception to November 26, 2025. Studies enrolling adults with acute or recurrent pericarditis treated with oral corticosteroids were included. Randomized trials, cohort studies, and case–control studies reporting clinical outcomes were eligible. Risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). Data were synthesized descriptively due to anticipated clinical and methodological heterogeneity. Results: Ten studies (2 prospective, 8 retrospective) including 2632 patients (800 corticosteroid-treated) met inclusion criteria. Prednisone was most frequently studied, with heterogeneous dosing (0.25–1.0 mg/kg/day) and non-standardized tapering strategies. Follow-up ranged from 1 to 6.7 years, and overall risk of bias was moderate with limited adjustment for confounding. Findings on recurrence were inconsistent in acute idiopathic and post-procedure pericarditis, while most studies in recurrent pericarditis reported higher recurrence with corticosteroid exposure. Conclusions: Evidence evaluating oral corticosteroids in pericarditis is limited by heterogeneity, confounding, and inconsistent reporting of treatment strategies. Observational data show variable associations with recurrence across clinical contexts. High-quality randomized trials stratified by pericarditis etiology and acuity are needed to define the optimal use of corticosteroids in pericarditis.
Prolonged postoperative dysphagia reduces return to work and physical activity after cervical spine surgery
Kussow, Nathan J. , Tippins, Nicholas P., Foreit, Anne M., Milne, Catherine, Narayanan, A., Neely, Matthew R., Reasoner, Jake T., Hannon, Kathleen M., Rezner, Aidan C., Alentado, Vincent J., Bisson, Erica F., Porche, Ken, Foley, Kevin T., Potts, Eric A., Milne, Catherine M., Alentado, Vincent J. , Bisson, Erica F. , Porche, Ken, Foley, Kevin T. , Potts, Eric A.

Mayo Clinic

Journal of Neurosurgery: Spine | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2026.3.spine251536 | PMID 42566788 Get It

OBJECTIVE Dysphagia has been shown to have an adverse effect on patient quality of life following cervical spine surgery, but its impact on patients’ ability to return to work (RTW) and return to physical activities (RTA) has never been investigated. This study aimed to evaluate the impact of postoperative dysphagia on patients’ ability to RTW and RTA after surgery. METHODS A prospectively maintained multi-institutional spine registry of patients who underwent cervical spine surgery between 2016 and 2023 was retrospectively reviewed. An Eating Assessment Tool-10 (EAT-10) score ≥ 3 was used to quantify preoperative and 12-month postoperative dysphagia. Prolonged dysphagia was defined as new dysphagia present at 12 months among patients without baseline dysphagia. RTW and RTA were assessed at baseline and 12 months postoperatively. Mixed-effects logistic regressions were used to evaluate the effect of dysphagia on RTW and RTA. RESULTS Of the 1208 patients meeting inclusion criteria, 240 (20%) experienced prolonged dysphagia, of whom 208 (87%) underwent anterior surgery. Preoperatively, 709 (59%) patients were fully employed or on short-term leave, 307 (25%) were retired, and 191 (16%) were otherwise unemployed. At the 12-month follow-up, RTW and RTA status were collected for 629 (95%) of the 664 employed patients who planned to RTW after surgery and 1127 (93%) of the total cohort, respectively. Significantly lower rates of RTW (86% vs 96%, p < 0.001) and RTA (62% vs 79%, p < 0.001) were observed in patients with prolonged dysphagia. Multivariable analysis identified dysphagia as being independently associated with lower odds of RTW (OR 0.35, 95% CI 0.14–0.86; p = 0.022) and RTA (OR 0.44, 95% CI 0.31–0.63; p < 0.001). CONCLUSIONS Prolonged postoperative dysphagia—defined as a new EAT-10 score ≥ 3 at 12 months—was associated with substantially lower odds of returning to work and physical activities after cervical spine surgery, underscoring the importance of dysphagia prevention and management in postoperative care.
Pediatric sarcomas: challenges and opportunities
Gao, Yuan, Bailey, Kelly M. , Blackman, Samuel C. , Bushweller, John H. , Chong, Shasha , DeHond, Kevin, Grembecka, Jolanta , Hatley, Mark E. , Kadoch, Cigall , Koehler, Angela N. , Linardic, Corinne M. , Renna, Phil, Stewart, Elizabeth A., Stillman, Bruce , Sweet-Cordero, E. Alejandro, Reu, Frederic J , Stillman, Bruce , Stegmaier, Kimberly , Vakoc, Christopher R , Guenther, Lillian M , Reu, Frederic J. , Rivera, Miguel N. , Stewart, Elizabeth A. , Sweet-Cordero, Alejandro

Mayo Clinic

Genes & Development | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353549.125 | PMID 42552078 Get It

Pediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancements in research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.
From High Cost to High Access: The Impact of Generic Abiraterone on Medicare Part D Spending in Advanced Prostate Cancer
Lee, Matthew S. , Kim, Tae-Hee , Roberson, Daniel S. , Sharma, Vidit , Wymer, Kevin , Kwon, Eugene D, Karnes, R Jeffrey, Boorjian, Stephen A. , Khanna, Abhinav

Mayo Clinic

Urology Practice | August 4, 2026 | Volume: 13 | Issue: 6 | Pages: 580-587

10.1097/upj.0000000000001066 | PMID 42550948 Get It